Bone Mineral Density in patients with Myelomeningocele

Patients and methods Eighty patients with myelomeningocele were randomly chosen from a roster of > 500 patients with (MMC) followed at a multidisciplinary spina bifida unit in a thirdlevel public university hospital, which serves as the referral centre for these patients in our country. Patients with known metabolic acidosis, renal insufficiency, or other metabolic bone disease (i.e., hyperparathyroidism) were excluded from this study. We measured Bone Mineral Density (BMD) with total-body DXA scan with subregional areas values and the biochemical markers of bone mineral metabolism in blood and urine. To study relationships among the variables, the Chi-squared, ANOVA and lineal regression tests were applied